Please login to the form below

Not currently logged in
Email:
Password:

GSK launches first-in-class epilepsy drug

GSK introduces Trobalt for the adjunct treatment of adults with partial-onset seizures

GlaxoSmithKline (GSK) has launched Trobalt (retigabine), the first in a new class of anti-epileptic drug (AED), for the adjunct treatment of adults with partial-onset seizures, and demonstrated significant effects in a treatment resistant patient population.

Retigabine is the first AED to target neuronal potassium channels, which are involved in inhibitory mechanisms in the brain. Inhibitory mechanisms are thought to have a role in seizure control.

Professor Martin J Brodie, director of the epilepsy unit at Western Infirmary, Glasgow, UK, said: "Trobalt represents a positive addition to the therapeutic armamentarium for the many adult patients with inadequately-controlled focal onset seizures."

The efficacy and safety of retigabine was established in two pivotal multicentre, randomised, double-blind, placebo-controlled, fixed dose studies where patients who were treatment resistant were recruited. Retigabine significantly improved seizure control, with a greater number of patients achieving a reduction in the number of seizures by 50 per or more, compared with placebo.

Retigabine, referred to as ezogabine in the US, is being jointly developed by GSK and Valeant.

17th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....